None
Quote | Sutro Biopharma Inc. (NASDAQ:STRO)
Last: | $2.96 |
---|---|
Change Percent: | 0.33% |
Open: | $3.04 |
Close: | $2.96 |
High: | $3.04 |
Low: | $2.82 |
Volume: | 621,269 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Sutro Biopharma Inc. (NASDAQ:STRO)
2024-05-20 09:58:08 ET More on premarkets gainers & stock Crown ElectroKinetics Corp. (CRKN) Q1 2024 Earnings Call Transcript Crown ElectroKinetics Corp. (CRKN) Q4 2023 Earnings Call Transcript Financial information for Crown ElectroKinetics Financial inf...
2024-05-13 17:18:12 ET More on Sutro Biopharma BofA starts Sutro at buy, cites ovarian cancer drug candidate Sutro Biopharma prices $75M underwritten offering Seeking Alpha’s Quant Rating on Sutro Biopharma Historical earnings data for Sutro Biopharma ...
Message Board Posts | Sutro Biopharma Inc. (NASDAQ:STRO)
Subject | By | Source | When |
---|---|---|---|
AviseAnalytics: 4 BIOTECH STOCKS THAT WARRANT YOUR ATTENTION! $STRO $MTEM $SNDX $KRYS Clinical-Stag | AviseAnalytics | investorshangout | 10/05/2021 12:40:31 PM |
News, Short Squeeze, Breakout and More Instantly...
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient expansion phase well underway in Phase 2 study of luvelta in combination with be...
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 have been enrolled and are in foll...
2024-04-03 17:00:02 ET Jay Olson from Oppenheimer issued a price target of $10.00 for STRO on 2024-04-03 14:01:00. The adjusted price target was set to $10.00. At the time of the announcement, STRO was trading at $5.09. The overall price target consensus is at $14.50 wit...